Goldman Sachs has topped the latest mergers and acquisitions (M&A) league table of the top 10 financial advisers for the Healthcare industry for Q3 2018, compiled by leading data analytics company GlobalData.
Goldman Sachs, an American bank, emerged as the clear winner by deal value, accumulating only four transactions, but worth a total of $13.3bn.
According to GlobalData, which uses its tracking of all merger and acquisition, private equity/venture capital and asset transaction activity globally to compile the league table, Barclays took the second spot with four deals worth $6.5bn, followed by JP Morgan with $5.7bn.
Prakhar Baghmar, Financial Deals Analyst at GlobalData, said: “Involvement in three big-ticket deals of the sector – LifePoint Health’s acquisition by Apollo Management for $5.6bn, China Biologic Products’ $3.9bn deal and Medtronic’s $3bn acquisition of Mazor Robotics – proved to be the driving factor for Goldman Sachs.”
Global Healthcare deals market Q3 2018
The Healthcare sector witnessed significantly low value and volume deals during the third quarter of 2018 compared to the same quarter in 2017. The total value crashed by 48.14% to $46.1bn in Q3 2018 from $88.9bn in Q3 2017, while volumes plunged by 34.9% from 953 to 620 during the period.
Goldman Sachs, which led the Healthcare league table of M&A financial advisers, achieved third rank in the global league table of top 20 M&A financial advisers recently released by GlobalData. Citi topped the global rankings, though it stood fifth in the Healthcare league table list for the quarter.
Skadden Arps Slate Meagher & Flom lead the M&A legal advisers ranking list
US-based law firm Skadden Arps Slate Meagher & Flom was the leading player in the top 10 legal advisers by value. The firm advised on the maximum number of deals, worth a total $6.6bn, which helped it to topple its competitors despite not advising on the quarter’s top deal. Kirkland & Ellis and Ropes & Gray equaled the top-ranked Skadden in volume terms but settled at sixth and seventh ranks owing to low-value deals.